A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses

Breast Cancer Research and Treatment

Volumn 112, Issue 3, 2008, Pages 533-543

  Cameron, David ^a,b   Casey, Michelle ^c   Press, Michael ^d   Lindquist, Deborah ^e   Pienkowski, Tadeusz ^f   Romieu, C Gilles ^g   Chan, Stephen ^h   Jagiello Gruszfeld, Agnieszka ⁱ   Kaufman, Bella ^j   Crown, John ^k   Chan, Arlene ^l   Campone, Mario ^m   Viens, Patrice ⁿ   Davidson, Neville ^o   Gorbounova, Vera ^p   Raats, Johannes Isaac ^q   Skarlos, Dimosthenis ^r   Newstat, Beth ^c   Roychowdhury, Debasish ^c   Paoletti, Paolo ^c   Oliva, Cristina ^c   Rubin, Stephen ^c   Stein, Steven ^c   Geyer, Charles E ^s   more..

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b NCRN Co ordinating Centre   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^f INSTITUTE OF ONCOLOGY   (Poland)

^g CENTRE VAL D AURELLE   (France)

^h NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

ⁱ Chemotherapy Department   (Poland)

^j SHEBA MEDICAL CENTER   (Israel)

^k All Ireland Cooperative Oncology Research Group   (Ireland)

^l Mount Hospital   (Australia)

^m CENTRE RENÉ GAUDUCHEAU   (France)

ⁿ INSTITUT PAOLI CALMETTES   (France)

^o BROOMFIELD HOSPITAL   (United Kingdom)

^p Cancer Research Center   (Russian Federation)

^q Panorama Medi Clinic   (South Africa)

^r Errikos Dunant Hospital   (Greece)

^s ALLEGHENY GENERAL HOSPITAL   (United States)

more..

Author keywords

Advanced breast cancer; Biomarker; Capecitabine; Dual tyrosine kinase inhibitor; HER2 positive; Lapatinib; Metastatic breast cancer; Phase III

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KAPLAN MEIER METHOD; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; ONCOGENE NEU; PHASE 3 CLINICAL TRIAL; PRINZMETAL ANGINA PECTORIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; TUMOR MARKERS, BIOLOGICAL;

EID: 56549113680     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-007-9885-0     Document Type: Article

References (19)

1. DF Stern 2000 Tyrosine kinase signaling in breast cancer: ErbB family receptor tyrosine kinases Breast Cancer Res 2 176 183
2. DJ Slamon GM Clark SG Wong 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182
3. MF Press DJ Slamon KJ Flom J Park J-Y Zhou L Bernstein 2002 Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens J Clin Oncol 20 3095 3105
4. MA Cobleigh CL Vogel D Tripathy 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639 2648
5. CL Vogel MA Cobleigh D Tripathy 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719 726
6. DJ Slamon B Leyland-Jones S Shak 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792
7. EH Romond EA Perez J Bryant 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684
8. Smith I, Procter M, Gelber RD et al for the HERA study team (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29-36
9. Y Lu X Zi Y Zhao 2001 Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) J Natl Cancer Inst 93 1852 1857
10. O Segatto CR King JH Pierce 1988 Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene Mol Cell Biol 8 5570 5574
11. PP Di Fiore JH Pierce MH Kraus 1987 erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells Science 237 178 182
12. Hayes DF, Yamauchi H, Broadwater G et al for the Cancer and Leukemia Group B (2001) Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7:2703-2711
13. CE Geyer J Forster D Lindquist 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743
14. P Therasse SG Arbuck EA Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
15. RD Mass MF Press S Anderson 2005 Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab Clin Breast Cancer 6 240 246
16. TI Andersen E Paus JM Nesland 1995 Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumor Acta Oncol 34 499 504
17. R Colomer S Montero A Lluch 2000 Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer Clin Cancer Res 6 2356 2362
18. H Yamauchi A O'Neill R Gelman 1997 Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein J Clin Oncol 15 2518 2525
19. FJ Esteva V Valero D Booser 2002 Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer J Clin Oncol 20 1800 1808